Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas.

Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KSJ, Betz BL, Carey TE, Brown NA.

Ann Oncol. 2018 Feb 1;29(2):466-471. doi: 10.1093/annonc/mdx736.

PMID:
29145573
2.

Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, Landau C, Shao L, Roulston D, Wang L, Siddiqui J, Cao X, Magi-Galluzzi C, Zhang M, Osunkoya AO, Smith SC, McKenney JK, Betz BL, Myers JL, Chinnaiyan AM, Tomlins SA, Mehra R.

Mod Pathol. 2018 Jan;31(1):179-197. doi: 10.1038/modpathol.2017.99. Epub 2017 Aug 25.

PMID:
28840857
3.

Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma.

Brown NA, Lew M, Weigelin HC, Weizer AZ, Montgomery JS, Betz BL, Mehra R.

Histopathology. 2018 Jan;72(2):354-356. doi: 10.1111/his.13318. Epub 2017 Oct 12. No abstract available.

PMID:
28741734
4.

Cutaneous syncytial myoepithelioma: A recently described neoplasm which may mimic nevoid melanoma and epithelioid sarcoma.

Alomari AK, Brown N, Andea AA, Betz BL, Patel RM.

J Cutan Pathol. 2017 Oct;44(10):892-897. doi: 10.1111/cup.13005. Epub 2017 Aug 2.

PMID:
28708250
5.

Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy.

Upadhyaya SA, Koschmann C, Muraszko K, Venneti S, Garton HJ, Hamstra DA, Maher CO, Betz BL, Brown NA, Wahl D, Weigelin HC, DuRoss KE, Leonard AS, Robertson PL.

J Child Neurol. 2017 Feb;32(2):194-203. doi: 10.1177/0883073816675547. Epub 2016 Nov 3.

6.

The utility of ETV1, ETV4 and ETV5 RNA in-situ hybridization in the diagnosis of CIC-DUX sarcomas.

Smith SC, Palanisamy N, Martin E, Almenara J, McHugh JB, Choi EK, Lucas DR, Betz BL, Thomas D, Patel RM.

Histopathology. 2017 Mar;70(4):657-663. doi: 10.1111/his.13112. Epub 2016 Dec 16.

PMID:
27790742
7.

Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma.

Udager AM, McHugh JB, Betz BL, Montone KT, Livolsi VA, Seethala RR, Yakirevich E, Iwenofu OH, Perez-Ordonez B, DuRoss KE, Weigelin HC, Lim MS, Elenitoba-Johnson KS, Brown NA.

J Pathol. 2016 Aug;239(4):394-8. doi: 10.1002/path.4750. Epub 2016 Jul 1.

8.

Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.

Kim MM, Camelo-Piragua S, Schipper M, Tao Y, Normolle D, Junck L, Mammoser A, Betz BL, Cao Y, Kim CJ, Heth J, Sagher O, Lawrence TS, Tsien CI.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):305-11. doi: 10.1016/j.ijrobp.2015.10.032. Epub 2015 Nov 10.

9.

Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries.

Brown NA, Betz BL.

Biomark Cancer. 2015 Oct 4;7(Suppl 2):19-24. doi: 10.4137/BIC.S29329. eCollection 2015. Review.

10.

Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S├ęzary syndrome.

Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS.

Nat Commun. 2015 Sep 29;6:8470. doi: 10.1038/ncomms9470.

11.

High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.

Udager AM, Rolland DCM, McHugh JB, Betz BL, Murga-Zamalloa C, Carey TE, Marentette LJ, Hermsen MA, DuRoss KE, Lim MS, Elenitoba-Johnson KSJ, Brown NA.

Cancer Res. 2015 Jul 1;75(13):2600-2606. doi: 10.1158/0008-5472.CAN-15-0340. Epub 2015 Apr 30.

12.

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA.

Neoplasia. 2015 Apr;17(4):385-99. doi: 10.1016/j.neo.2015.03.004.

13.

Integrative molecular profiling of routine clinical prostate cancer specimens.

Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA.

Ann Oncol. 2015 Jun;26(6):1110-8. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.

14.

Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.

Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG.

Am J Clin Pathol. 2015 Jan;143(1):89-99. doi: 10.1309/AJCPDN4Q1JTFGCFC.

PMID:
25511147
15.

A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.

Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2015 Jan;17(1):76-84. doi: 10.1016/j.jmoldx.2014.09.007. Epub 2014 Nov 6. Erratum in: J Mol Diagn. 2015 Mar;17(2):206.

PMID:
25468431
16.

A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.

Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, Betz BL, Brown NA, Hristov AC, Wilcox RA, Miranda RN, Medeiros LJ, Jeon YK, Inamdar KV, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Dec 11;124(25):3768-71. doi: 10.1182/blood-2014-07-588434. Epub 2014 Oct 27.

17.

Clear cell melanoma: a cutaneous clear cell malignancy.

Pletneva MA, Andea A, Palanisamy N, Betz BL, Carskadon S, Wang M, Patel RM, Fullen DR, Harms PW.

Arch Pathol Lab Med. 2014 Oct;138(10):1328-36. doi: 10.5858/arpa.2014-0307-CC. Review.

PMID:
25268196
18.

Activating FGFR2-RAS-BRAF mutations in ameloblastoma.

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL.

Clin Cancer Res. 2014 Nov 1;20(21):5517-26. doi: 10.1158/1078-0432.CCR-14-1069. Epub 2014 Jul 3.

19.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.

20.

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13.

21.

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

Fanta PT, Sicklick JK, Betz BL, Peterson MR.

J Clin Oncol. 2015 Mar 10;33(8):e41-4. doi: 10.1200/JCO.2013.50.0082. Epub 2014 Mar 17. No abstract available.

22.

Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays.

Brown NA, Weigelin HC, Bailey N, Laliberte J, Elenitoba-Johnson KS, Lim MS, Betz BL.

Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):590-600. doi: 10.1097/PAI.0000000000000024.

PMID:
24503706
23.

Mycosis fungoides with CD20 expression: report of two cases and review of the literature.

Harms KL, Harms PW, Anderson T, Betz BL, Ross CW, Fullen DR, Hristov AC.

J Cutan Pathol. 2014 Jun;41(6):494-503. doi: 10.1111/cup.12299. Epub 2014 Feb 26. Review.

24.

At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases.

Smith SC, Palanisamy N, Betz BL, Tomlins SA, Mehra R, Schmidt LA, Lucas DR, Myers JL.

Histopathology. 2014 Jul;65(1):144-6. doi: 10.1111/his.12354. Epub 2014 Mar 14. No abstract available.

25.

Detection of MPL mutations by a novel allele-specific PCR-based strategy.

Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2013 Nov;15(6):810-8. doi: 10.1016/j.jmoldx.2013.07.006. Epub 2013 Aug 28.

PMID:
23994117
26.

A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations.

Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2013 Sep;15(5):592-9. doi: 10.1016/j.jmoldx.2013.04.006. Epub 2013 Jun 28.

PMID:
23810504
27.

The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.

Betz BL, Dixon CA, Weigelin HC, Knoepp SM, Roh MH.

Cancer Cytopathol. 2013 Sep;121(9):489-99. doi: 10.1002/cncy.21286. Epub 2013 Mar 27.

28.

Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.

Bernacki KD, Betz BL, Weigelin HC, Lao CD, Redman BG, Knoepp SM, Roh MH.

Am J Clin Pathol. 2012 Nov;138(5):670-7. doi: 10.1309/AJCPEQJW3PLOOZTC.

PMID:
23086767
29.

Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS.

J Exp Med. 2012 Aug 27;209(9):1553-65. doi: 10.1084/jem.20120910. Epub 2012 Aug 13.

30.

The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma.

Betz BL, Roh MH, Weigelin HC, Placido JB, Schmidt LA, Farmen S, Arenberg DA, Kalemkerian GP, Knoepp SM.

Am J Clin Pathol. 2011 Oct;136(4):564-71. doi: 10.1309/AJCP84TUTQOSUONG.

PMID:
21917678
31.

Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma.

Hookim K, Roh MH, Willman J, Placido J, Weigelin HC, Fields KL, Pang J, Betz BL, Knoepp SM.

Cancer Cytopathol. 2012 Feb 25;120(1):52-61. doi: 10.1002/cncy.20180. Epub 2011 Jul 25.

32.

Acute myeloid leukemia diagnosis in the 21st century.

Betz BL, Hess JL.

Arch Pathol Lab Med. 2010 Oct;134(10):1427-33. doi: 10.1043/2010-0245-RA.1. Review.

PMID:
20923295
33.

Identification of a specific motif of the DSS1 protein required for proteasome interaction and p53 protein degradation.

Wei SJ, Williams JG, Dang H, Darden TA, Betz BL, Humble MM, Chang FM, Trempus CS, Johnson K, Cannon RE, Tennant RW.

J Mol Biol. 2008 Nov 14;383(3):693-712. doi: 10.1016/j.jmb.2008.08.044. Epub 2008 Aug 26.

PMID:
18775730
34.
35.

Hybrid capture of putative tumor suppressor genes.

Betz BL, Weissman BE.

Methods Mol Biol. 2003;222:365-73. No abstract available.

PMID:
12710698
36.

Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.

Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE.

Oncogene. 2002 Aug 8;21(34):5193-203.

37.

Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.

Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W Jr, Murchardt C, Yaniv M, Sherman LS, Knudsen ES, Weissman BE.

Oncogene. 2002 Feb 14;21(8):1196-207.

38.

Identification of candidate liver tumor suppressor genes from human 11p11.2-p12.

Ricketts SL, Garcia NF, Betz BL, Coleman WB.

Genes Chromosomes Cancer. 2002 Jan;33(1):47-59.

PMID:
11746987
39.

Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling.

Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES.

J Biol Chem. 2002 Feb 15;277(7):4782-9. Epub 2001 Nov 21.

40.

Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.

Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE.

J Cell Physiol. 2001 Jan;186(1):136-45.

PMID:
11147808
41.

Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.

DeCristofaro MF, Betz BL, Wang W, Weissman BE.

Oncogene. 1999 Dec 9;18(52):7559-65.

Supplemental Content

Support Center